ME: 23andMe Holding Co. Stock

by  •  • Comments Off on ME: 23andMe Holding Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 243.68
Enterprise Value ($M) 1.26
Book Value ($M) 377.19
Book Value / Share 0.78
Price / Book 0.65
NCAV ($M) 78.94
NCAV / Share 0.16
Price / NCAV 3.09

Profitability (mra)
Return on Invested Capital (ROIC) -1.14
Return on Assets (ROA) -0.55
Return on Equity (ROE) -0.73

Liquidity (mrq)
Quick Ratio 2.04
Current Ratio 2.15

Balance Sheet (mrq) ($M)
Current Assets 309.96
Assets 608.21
Liabilities 231.02
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-17 13D/A ABeeC 2.0, LLC 25.80 7.38
02-13 13G/A Vanguard Group Inc 7.24 -17.04
01-26 13G BlackRock Inc. 7.20

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPOR
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 899,789 2,048,255 43.93
2024-05-02 990,105 2,428,692 40.77
2024-05-01 890,601 584,375 152.40
2024-04-30 565,134 1,176,269 48.04
2024-04-29 1,095,707 804,955 136.12

(click for more detail)

Similar Companies
LYEL – Lyell Immunopharma, Inc. MCRB – Seres Therapeutics, Inc.
MDGL – Madrigal Pharmaceuticals, Inc. MGNX – MacroGenics, Inc.
MGTX – MeiraGTx Holdings plc


Financial data and stock pages provided by
Fintel.io